Adial Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Adial Pharmaceuticals, Inc. (ADIL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $22.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.30M.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.38M, a 163.00% decline year-over-year.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $2.20M.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$1.69M, a 125.49% decline year-over-year.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $2.13M, a 130.73% increase from fiscal 2024.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $923.44K.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.17M.
- Adial Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$2.06M, a 224.04% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $22.83M 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | -$1.30M 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | $2.13M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $855.76K 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $2.16M 10-Q · filed 2026-08-14 | $2.16M 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | -$1.38M 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | $923.44K 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | $460.97K 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | -$1.17M 10-K · filed 2025-03-04 | ||||
| 2023-09-30 | -$3.69M 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | -$2.78M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | -$1.69M 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | -$2.06M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$309.51K 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $3.09M 10-Q/A · filed 2023-10-30 | ||||
| 2022-03-31 | $6.63M 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | $1.66M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $2.78M 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $808.73K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $1.24M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$2.38M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $588.10K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $1.85M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | -$1.83M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |